- Insider Monkey•3 days ago
Novartis AG (NYSE:NVS) has announced that the Phase III EXPAND study, which is evaluating the efficacy and safety of oral, once daily, BAF312 in secondary progressive multiple sclerosis (SPMS), has met its primary endpoint of reducing the risks of disability progression, compared with placebo. The EXPAND study represented the largest randomized, controlled study in SPMS to date. It […]
- Zacks•3 days ago
Novartis AG (NVS) announced positive results from the phase III EXPAND study on its multiple sclerosis candidate BAF312.
- Motley Fool•5 days ago
A patent review board rules that claims on Teva Pharmaceuticals' three-times-weekly version of Copaxone aren't patentable.
NOVARTIS AG CEDEAR EACH REP 0.5 (NVS.BA)
Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
|Day's Range||590.00 - 590.00|
|52wk Range||590.00 - 605.50|
|1y Target Est||N/A|
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||110|
|Dividend & Yield||N/A (N/A)|